Alvin Luk

4.5k total citations
18 papers, 583 citations indexed

About

Alvin Luk is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alvin Luk has authored 18 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alvin Luk's work include Biosimilars and Bioanalytical Methods (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and CAR-T cell therapy research (5 papers). Alvin Luk is often cited by papers focused on Biosimilars and Bioanalytical Methods (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and CAR-T cell therapy research (5 papers). Alvin Luk collaborates with scholars based in China, United States and Ukraine. Alvin Luk's co-authors include Haiyan Jiang, Glenn F. Pierce, Jürg M. Sommer, Jerry S. Powell, Margaret V. Ragni, Neil C. Josephson, Gregory Cheng, Jaya Goyal, Jennifer Dumont and Valder R. Arruda and has published in prestigious journals such as Blood, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

Alvin Luk

18 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alvin Luk China 7 339 245 173 129 73 18 583
Mariëtte Boon‐Spijker Netherlands 7 110 0.3× 252 1.0× 277 1.6× 119 0.9× 21 0.3× 10 424
Bagirath Gangadharan United States 15 350 1.0× 291 1.2× 301 1.7× 240 1.9× 54 0.7× 37 677
Erin Burnett Canada 7 254 0.7× 89 0.4× 71 0.4× 68 0.5× 39 0.5× 12 352
Douglas Drager United States 6 180 0.5× 147 0.6× 97 0.6× 51 0.4× 48 0.7× 7 317
H.H. Brackmann Germany 8 412 1.2× 152 0.6× 69 0.4× 36 0.3× 42 0.6× 14 512
Erin L. Kuether United States 11 308 0.9× 143 0.6× 181 1.0× 134 1.0× 10 0.1× 15 433
Nathalie Enjolras France 10 209 0.6× 131 0.5× 54 0.3× 26 0.2× 9 0.1× 24 326
Vaia Stavropoulou Switzerland 9 212 0.6× 269 1.1× 24 0.1× 125 1.0× 13 0.2× 18 417
Seiki Kamisue Japan 12 532 1.6× 127 0.5× 73 0.4× 47 0.4× 77 1.1× 17 605
Cynthia Schultz United States 10 144 0.4× 167 0.7× 36 0.2× 36 0.3× 29 0.4× 12 339

Countries citing papers authored by Alvin Luk

Since Specialization
Citations

This map shows the geographic impact of Alvin Luk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alvin Luk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alvin Luk more than expected).

Fields of papers citing papers by Alvin Luk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alvin Luk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alvin Luk. The network helps show where Alvin Luk may publish in the future.

Co-authorship network of co-authors of Alvin Luk

This figure shows the co-authorship network connecting the top 25 collaborators of Alvin Luk. A scholar is included among the top collaborators of Alvin Luk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alvin Luk. Alvin Luk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Pang, Long, Xin Zhang, Alvin Luk, et al.. (2023). Leber’s Hereditary Optic Neuropathy with Mitochondrial DNA Mutation G11778A: A Systematic Literature Review and Meta‐Analysis. BioMed Research International. 2023(1). 1107866–1107866. 3 indexed citations
2.
Zhu, Xiaodong, Yanhua Ding, Wenjia Zhou, et al.. (2020). A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Cancer Chemotherapy and Pharmacology. 87(3). 349–359. 16 indexed citations
3.
4.
5.
Xu, Binghe, Q. Zhang, Tao Sun, et al.. (2019). Efficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer: A phase III trial. Annals of Oncology. 30. v106–v107. 2 indexed citations
6.
Shi, Yuan, Yan Qin, Zhao Shan, et al.. (2019). A population pharmacokinetic model: Assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma. Annals of Oncology. 30. ix91–ix91. 1 indexed citations
7.
Xu, Binghe, Q. Zhang, Tao Sun, et al.. (2019). First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer. Annals of Oncology. 30. ix185–ix185. 3 indexed citations
8.
Chen, Guiling, Min Wu, He Gao, et al.. (2019). FRI0086 CHINA-MANUFACTURED ADALIMUMAB BIOSIMILAR, HLX03, DEMONSTRATED PHARMACOKINETIC EQUIVALENCE AND COMPARABLE SAFETY TO REFERENCE ADALIMUMAB. Annals of the Rheumatic Diseases. 78. 706–706. 4 indexed citations
9.
Hou, Ming‐Mo, Ching‐Liang Ho, Weidong Jiang, et al.. (2019). A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck. Annals of Oncology. 30. ix26–ix27. 2 indexed citations
10.
Ho, C.L., et al.. (2019). A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy. Annals of Oncology. 30. ix109–ix110. 3 indexed citations
11.
Yu, Tong, Jian Sun, Min Wu, et al.. (2018). A China-manufactured bevacizumab biosimilar, HLX04, matches bevacizumab sourced from China, USA and the European Union. Annals of Oncology. 29. ix33–ix34. 2 indexed citations
12.
Shi, Yuankai, Q. Zhang, Xiao-Feng Han, et al.. (2018). First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). Annals of Oncology. 29. ix88–ix88. 3 indexed citations
13.
Powell, Jerry S., Neil C. Josephson, Doris Quon, et al.. (2012). Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 119(13). 3031–3037. 171 indexed citations
14.
Shapiro, Amy D., Margaret V. Ragni, Leonard A. Valentino, et al.. (2011). Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 119(3). 666–672. 134 indexed citations
15.
Powell, Jerry S., Diane J. Nugent, Jillian Harrison, et al.. (2008). Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. Journal of Thrombosis and Haemostasis. 6(2). 277–283. 45 indexed citations
16.
Powell, Jerry S., Diane J. Nugent, Jillian Harrison, et al.. (2008). Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. Journal of Thrombosis and Haemostasis. 6(2). 277–283. 15 indexed citations
17.
Jiang, Haiyan, Glenn F. Pierce, Margareth C. Ozelo, et al.. (2006). Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B. Molecular Therapy. 14(3). 452–455. 167 indexed citations
18.
High, Katherine A., Michael Tigges, Catherine S. Manno, et al.. (2004). Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.. Blood. 104(11). 413–413. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariëtte Boon‐Spijker Breakdown of academic impact, for papers by Bagirath Gangadharan Breakdown of academic impact, for papers by Erin Burnett Breakdown of academic impact, for papers by Douglas Drager Breakdown of academic impact, for papers by H.H. Brackmann Breakdown of academic impact, for papers by Erin L. Kuether Breakdown of academic impact, for papers by Nathalie Enjolras Breakdown of academic impact, for papers by Vaia Stavropoulou Breakdown of academic impact, for papers by Seiki Kamisue Breakdown of academic impact, for papers by Cynthia Schultz
Rankless by CCL
2026